BBHC
BPMC

Brown Brothers Harriman & Co’s Blueprint Medicines BPMC Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-157
Closed -$10K – 1277
2022
Q3 		$10K Buy
+157
New +$10.1K ﹤0.01% 1146
2021
Q3 		– Sell
-1,566
Closed -$138 – 1159
2021
Q2 		$138 Buy
+1,566
New +$143K ﹤0.01% 496
2016
Q3 		– Sell
-2,411
Closed -$49K – 782
2016
Q2 		$49K Hold
2,411
– – ﹤0.01% 450
2016
Q1 		$44K Hold
2,411
– – ﹤0.01% 453
2015
Q4 		$64K Buy
+2,411
New +$54.3K ﹤0.01% 434

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Brown Brothers Harriman & Co's BPMC Position: Q4 2022 in Review

Brown Brothers Harriman & Co sold out of Blueprint Medicines (BPMC) in Q4 2022, closing a stake of 157 shares — an estimated $10K sold.

Brown Brothers Harriman & Co first reported a position in BPMC in Q4 2015 and held it in 5 quarters. The position peaked at $64K in Q4 2015. 223 funds tracked by Wall St. Rank hold BPMC as of Q4 2022.

  • Brown Brothers Harriman & Co reported no remaining Blueprint Medicines position as of Q4 2022 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 157 Blueprint Medicines shares in Q4 2022, an estimated $10K.
  • Brown Brothers Harriman & Co first reported a position in Blueprint Medicines in Q4 2015 and held it in 5 quarters.
  • Brown Brothers Harriman & Co's Blueprint Medicines position peaked at $64K in Q4 2015.
  • 223 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q4 2022, filed 9 Feb 2023.